- Home
- BEAM vs GNL Comparison
BEAM vs GNL Comparison
Compare BEAM & GNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- GNL
- Stock Information
- Founded
- BEAM 2017
- GNL 2011
- Country
- BEAM United States
- GNL United States
- Employees
- BEAM N/A
- GNL N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- GNL Real Estate Investment Trusts
- Sector
- BEAM Health Care
- GNL Real Estate
- Exchange
- BEAM Nasdaq
- GNL Nasdaq
- Market Cap
- BEAM 1.8B
- GNL 1.7B
- IPO Year
- BEAM 2020
- GNL N/A
- Fundamental
- Price
- BEAM $16.19
- GNL $7.71
- Analyst Decision
- BEAM Strong Buy
- GNL Buy
- Analyst Count
- BEAM 11
- GNL 4
- Target Price
- BEAM $48.90
- GNL $9.50
- AVG Volume (30 Days)
- BEAM 1.9M
- GNL 1.4M
- Earning Date
- BEAM 05-06-2025
- GNL 05-07-2025
- Dividend Yield
- BEAM N/A
- GNL 13.17%
- EPS Growth
- BEAM N/A
- GNL N/A
- EPS
- BEAM N/A
- GNL N/A
- Revenue
- BEAM $63,578,000.00
- GNL $789,545,000.00
- Revenue This Year
- BEAM N/A
- GNL N/A
- Revenue Next Year
- BEAM $10.59
- GNL N/A
- P/E Ratio
- BEAM N/A
- GNL N/A
- Revenue Growth
- BEAM N/A
- GNL 38.85
- 52 Week Low
- BEAM $13.53
- GNL $6.51
- 52 Week High
- BEAM $35.25
- GNL $9.11
- Technical
- Relative Strength Index (RSI)
- BEAM 39.35
- GNL 48.91
- Support Level
- BEAM $15.35
- GNL $7.48
- Resistance Level
- BEAM $17.47
- GNL $7.95
- Average True Range (ATR)
- BEAM 0.90
- GNL 0.15
- MACD
- BEAM -0.07
- GNL -0.02
- Stochastic Oscillator
- BEAM 24.71
- GNL 38.79
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.